Volume 8 Number 11/12 November/December 2007
24 December 2007. Related: Editorial.
2007
11th European AIDS conference (EACS), October 24-27 2007, Madrid
2 December 2007. Related: Conference reports.
New European guidelines launched (2007)
2 December 2007. Related: Conference reports, Guidelines.
Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)
2 December 2007. Related: Conference reports, Antiretrovirals.
Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
2 December 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Drug interaction studies presented at EACS
1 December 2007. Related: Conference reports, PK and drug interactions, Basic science and immunology.
HIV and TB co-infection and treatment charges in the UK
1 December 2007. Related: Treatment access, TB coinfection.
US adult treatment guidelines updated (December 2007)
1 December 2007. Related: Guidelines.
Half-dose Kaletra tablet approved for paediatric use in the US
1 December 2007. Related: Antiretrovirals, Paediatric care.
Case report of efavirenz-associated nephrolithiasis
1 December 2007. Related: Side effects.
Yellow card reporting scheme for doctors and patients in the UK
1 December 2007. Related: Side effects.
US updates guidelines on use of ARVs during pregnancy (Dec 2007)
1 December 2007. Related: Pregnancy, Guidelines.
Perinatal transmission of HIV in England 2002-2005
1 December 2007. Related: Pregnancy.
Risk factors for in utero or intrapartum mother-to-child transmission in Thailand
1 December 2007. Related: Pregnancy.
New drug interaction summary tables: maraviroc, integrase inhibitors, etravirine, hormonal contraceptives
1 December 2007. Related: PK and drug interactions.
Acid reducing agents and protese inhibitors
1 December 2007. Related: PK and drug interactions.
Atazanavir, with or without ritonavir, may increase buprenorphine and buprenorphine metabolites, requiring dose adjustment
1 December 2007. Related: PK and drug interactions.
T-20 increases tipranavir levels but not hepatotoxicity
1 December 2007. Related: PK and drug interactions.
The effect of lopinavir/r on the renal clearance of tenofovir
1 December 2007. Related: PK and drug interactions.
Merck HIV vaccine trial is unblinded
1 December 2007. Related: Vaccines and microbicides.
IAS statement on US policy for HIV-positive visitors
1 December 2007. Related: Other news.
PLoS Medicine articles
1 December 2007. Related: On the web.
HIV/TB co-infection: meeting the challenge
1 December 2007. Related: On the web.
Volume 8 Number 11/12 November/December 2007 PDF
1 December 2007. Related: PDFs.
Volume 8 Number 10 October 2007
29 October 2007. Related: Editorial.
BHIVA Autumn conference, 11-12 October 2007, London
29 October 2007. Related: Conference reports.
Audit of treating naive patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3
2 October 2007. Related: Conference reports.
Donor governments pledge record amounts to the Global Fund
2 October 2007. Related: Treatment access.
Atripla approved in Europe as switch option for suppressed patients
2 October 2007. Related: Antiretrovirals.
Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients
2 October 2007. Related: Antiretrovirals.
Paediatric formulation of fosamprenavir approved in Europe
2 October 2007. Related: Antiretrovirals.
Raltegravir approved in the US
2 October 2007. Related: Antiretrovirals.
EMEA recommends reinstating license for Roches nelfinavir
2 October 2007. Related: Antiretrovirals.
Roche withdraw application for Biojector needle-free option for T-20
2 October 2007. Related: Antiretrovirals.
Antiretroviral drug exposure in the female genital tract
2 October 2007. Related: Women's health.
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women
2 October 2007. Related: Women's health.
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Womens Interagency HIV Study
2 October 2007. Related: Women's health.
Pregnancy shows a positive impact on HIV disease progression
2 October 2007. Related: Pregnancy.
African infants CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine prophylaxis
2 October 2007. Related: Pregnancy.
Low rates of mother to child transmission in the DREAM and MTCT-Plus programmes
2 October 2007. Related: Pregnancy.
Risk factors for early mortality for children receiving divided adult fixed dose combination tablets in Malawi
2 October 2007. Related: Paediatric care.
Risk of antibody negative HCV infection in four US HIV cohorts: risk linked to IDU, elevated ALT and low CD4 count
2 October 2007. Related: Hepatitis coinfection.
Survival of HIV-positive IDUs in the era of HAART
2 October 2007. Related: Treatment access.
Current or former injecting drug use is not related to earlier switch or discontinuation of HAART compared to non-IDU patients since 1999
2 October 2007. Related: Treatment strategies.
Merck HIV vaccine trial halted by DSMB for lack of efficacy
2 October 2007. Related: Vaccines and microbicides.
Free full text articles
2 October 2007. Related: On the web.
Conference abstracts and presentations
2 October 2007. Related: On the web.
Volume 8 Number 10 October 2007 PDF
1 October 2007. Related: PDFs.
Volume 8 Number 8/9 August/September 2007
24 September 2007. Related: Editorial.
Update on nelfinavir recall: plan for safety registries
3 September 2007. Related: Treatment alerts.
Pfizer issue Dear Doctor letter over EMS content in US formulation of nelfinavir
3 September 2007. Related: Treatment alerts.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney
3 September 2007. Related: Conference reports.
HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in people interrupting treatment in the SMART trial: new study to randomise people with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3
3 September 2007. Related: Conference reports, Treatment strategies.
CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r
3 September 2007. Related: Conference reports, Treatment strategies.
Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial
3 September 2007. Related: Conference reports, Antiretrovirals.
Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results
3 September 2007. Related: Conference reports, Antiretrovirals.
Importance of using maraviroc in combination with other active drugs in treatment-experienced patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Week 48 raltegravir results in treatment-naive phase II dose-finding study
3 September 2007. Related: Conference reports, Antiretrovirals.
DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs
3 September 2007. Related: Conference reports, Antiretrovirals.
Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r
3 September 2007. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r vs atazanvir/r in treatment-naive patients
3 September 2007. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young infants; interim results from the CHER study
3 September 2007. Related: Conference reports, Paediatric care.
Very low transmission rates among breastfeeding women receiving ART
3 September 2007. Related: Conference reports, Pregnancy.